On June 15, 2023, Acura Pharmaceuticals, Inc. entered into an agreement to further amend the June 28, 2019 License, Development and Commercialization Agreement with Abuse Deterrent Pharma, LLC ("AD Pharma"), for the development of LTX-03 (hydrocodone bitartrate with acetaminophen) immediate-release tablets utilizing Acura's patented LIMITx technology which addresses the consequences of excess oral administration of opioid tablets, the most prevalent route of opioid overdose and abuse. The amendment to the Agreement extends the FDA's acceptance date of a New Drug Application ("NDA") for LTX-03 to November 30, 2023 ("NDA Acceptance Date") ("Amended Agreement"). AD Pharma may terminate the Amended Agreement at any time.

Additionally, if the NDA for LTX-03 is not accepted by the FDA by the NDA Acceptance Date, AD Pharma may terminate the Amending Agreement and take ownership of the intellectual property rights of LTX-03 from the Company. Should AD Pharma choose not to exercise this option to terminate the Amended Agreement and the NDA for LTX -03 is subsequently accepted by the FDA, such option to terminate the Amended agreement expires.